C ANCA, or cytoplasmic antineutrophil cytoplasmic antibodies, are autoantibodies that target proteinase 3 (PR3) in neutrophil granules. They are a key biomarker for granulomatosis with polyangiitis (GPA), a form of small-vessel vasculitis linked to severe inflammation in the kidneys, lungs, and upper airways.
C ANCA is detected through indirect immunofluorescence and confirmed with enzyme-linked immunosorbent assay (ELISA). A positive result indicates immune system misdirection toward PR3, leading to neutrophil activation, endothelial damage, and tissue necrosis. This process underlies organ-specific injury in GPA and microscopic polyangiitis (MPA).
According to the American College of Rheumatology, c ANCA positivity occurs in 70-90% of GPA cases and 30-50% of MPA cases. Levels correlate with disease activity-elevated titers often precede relapse. Testing is essential for diagnosis, monitoring, and guiding therapy.
Neutrophils, a type of white blood cell, release granules containing enzymes like PR3 during infection or inflammation. In healthy individuals, these enzymes are tightly regulated. In people with c ANCA, the immune system produces antibodies that bind to PR3 on neutrophil surfaces.
When c ANCA binds to PR3, it triggers neutrophil activation and degranulation. Activated neutrophils adhere to blood vessel walls, releasing reactive oxygen species and proteolytic enzymes. This damages endothelial cells, promotes clotting, and recruits more inflammatory cells-leading to necrotizing vasculitis.
A 2021 study published in Arthritis & Rheumatology found that patients with high c ANCA titers had a 3.6-fold increased risk of renal flare within six months compared to those with low or negative levels. This highlights c ANCA's role not just in diagnosis but in predicting clinical course.
C ANCA is composed of IgG immunoglobulins directed against PR3. Unlike p ANCA (perinuclear ANCA), which targets myeloperoxidase (MPO), c ANCA shows a distinct cytoplasmic fluorescence pattern under microscope-bright, speckled staining throughout the cytoplasm of neutrophils.
There are two main types of ANCA based on antigen specificity:
| Type | Target Antigen | Associated Disease | Prevalence in Patients |
|---|---|---|---|
| C ANCA | Proteinase 3 (PR3) | Granulomatosis with polyangiitis (GPA) | 70-90% |
| P ANCA | Myeloperoxidase (MPO) | Microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA) | 30-50% |
While both ANCA types indicate autoimmune vasculitis, their clinical presentations differ. C ANCA-positive patients typically develop upper respiratory tract involvement-sinusitis, nasal ulcers-alongside pulmonary hemorrhage and rapidly progressive glomerulonephritis (RPGN).
C ANCA is not diagnostic on its own. A positive test must be interpreted alongside clinical symptoms, imaging, and biopsy results. False positives occur in 1-3% of healthy individuals and in chronic infections such as hepatitis C.
C ANCA testing is standard in evaluating unexplained systemic vasculitis, especially when patients present with hematuria, proteinuria, or pulmonary infiltrates. It is also used to monitor response to immunosuppressive therapy.
For example, a 42-year-old man presented with persistent sinus congestion, hemoptysis, and worsening kidney function. Urinalysis showed red blood cell casts. Serum creatinine was 3.2 mg/dL. ANCA testing revealed a c ANCA titer of 1:1280. Renal biopsy confirmed pauci-immune necrotizing glomerulonephritis. He was diagnosed with GPA and began treatment with cyclophosphamide and corticosteroids. After six months, c ANCA levels dropped to 1:40, and kidney function improved.
The European League Against Rheumatism (EULAR) guidelines recommend ANCA testing in patients with suspected small-vessel vasculitis, particularly when renal or pulmonary symptoms are present. Testing is not routine in asymptomatic individuals due to low specificity.
C ANCA is frequently mistaken for a standalone disease. It is not. It is a serological marker indicating immune dysregulation. Some assume a positive c ANCA means active disease-but levels can remain elevated after remission, and some patients stay seropositive indefinitely without symptoms.
Another misconception is that c ANCA causes vasculitis directly. While it contributes to neutrophil activation, the exact trigger remains unknown. Genetic predisposition (HLA-DRB1*04:01), environmental factors (smoking, silica exposure), and microbial mimicry may initiate the autoimmune cascade.
C ANCA is sometimes confused with ANA (antinuclear antibodies), which are associated with lupus. Unlike ANA, c ANCA is specific to small-vessel vasculitis and does not cross-react with nuclear antigens. A patient with c ANCA and positive ANA likely has overlap syndrome, requiring tailored management.
I observed this in a patient with mixed connective tissue disease who initially tested positive for both c ANCA and ANA. Despite no signs of vasculitis, her c ANCA titer remained stable. We avoided unnecessary immunosuppression until clinical evidence emerged.
C ANCA is a critical tool in diagnosing and managing ANCA-associated vasculitis. It identifies a subset of autoimmune diseases driven by neutrophil-mediated injury. Understanding its limitations-false positives, persistence post-treatment-is important for accurate interpretation.
When c ANCA is detected, clinicians must integrate results with clinical findings. Treatment decisions depend on organ involvement, not antibody status alone. Early intervention improves outcomes, especially in preventing irreversible kidney damage.